Be Biopharma Revenue and Competitors

Boston, MA USA

Location

$264M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Be Biopharma's estimated annual revenue is currently $18.6M per year.(i)
  • Be Biopharma's estimated revenue per employee is $155,000
  • Be Biopharma's total funding is $264M.

Employee Data

  • Be Biopharma has 120 Employees.(i)
  • Be Biopharma grew their employee count by -14% last year.

Be Biopharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VPReveal Email/Phone
3
Co-founder & VP, Strategy & OperationsReveal Email/Phone
4
VP Clinical Development OperationsReveal Email/Phone
5
VP, Business OperationsReveal Email/Phone
6
VP, External Manufacturing & Supply ChainReveal Email/Phone
7
Head ImmunologyReveal Email/Phone
8
SVP - Commercial and Franchise StrategyReveal Email/Phone
9
VP Non-Clinical DevelopmentReveal Email/Phone
10
SVP Clinical DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.7M82-45%$107.3MN/A
#2
$0.2M1-50%N/AN/A
#3
$6.2M4021%N/AN/A
#4
$42.2M2184%$165MN/A
#5
$14.6M94-37%$312.8MN/A
#6
$0.3M2-67%N/AN/A
#7
$235M366-5%$340.9MN/A
#8
$56M289-7%$7.6MN/A
#9
$4.7M6136%N/AN/A
#10
$2M138%N/AN/A
Add Company

What Is Be Biopharma?

Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.

keywords:N/A

$264M

Total Funding

120

Number of Employees

$18.6M

Revenue (est)

-14%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Be Biopharma News

2022-04-20 - Undeterred by gene therapy's struggles, a startup launches ...

Greenwald, however, is taking a long-term view, betting that interest in gene therapy research will be there once the downturn is over. “The...

2022-04-13 - Be Biopharma Closes $130M Financing

Be Biopharma, a Cambridge, MA-based developer of Engineered B Cell Medicines (BeCM), closed a $130m financing.

2022-04-06 - Be Bio Closes $130 Million Financing to Pioneer Engineered ...

--(BUSINESS WIRE)--Be Biopharma (“Be Bio”), a pioneer in the discovery and development of Engineered B Cell Medicines (BeCM), today announced...

2020-10-26 - Be Biopharma Raises $52M in Series A Financing

Be Biopharma, a Cambridge, MA-based company developing B cells as medicines, raised $52m in Series A financing. The round was led by Atlas Venture and RA Capital Management joined by Alta Partners, Longwood Fund and Takeda Ventures. The company plans to use the funds to precisely engineer B ce ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.1M12025%N/A
#2
$38.8M120N/AN/A
#3
$18.6M1203%N/A
#4
$17.6M12019%$89M
#5
$30.4M12121%N/A